Drug Profile
Cavisomes
Latest Information Update: 27 Jul 1999
Price :
$50
*
At a glance
- Originator Bayer HealthCare Pharmaceuticals
- Class Contrast media
- Mechanism of Action Ultrasonography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 27 Jul 1999 No Development Reported - Investigation in Cancer (diagnosis) in USA (unspecified route)
- 09 Apr 1997 Investigation in Cancer (diagnosis) in USA (unspecified route)